Iron Triangle Partners LP
13F Reported Value
ⓘ$874.7M
Holdings
27
Latest Filing
2025-12-31
Filing Quarter
Q4 2025
Portfolio Overview
Iron Triangle Partners LP disclosed 27 positions worth $874.7M in its Form 13F-HR for Q4 2025, led by $CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.) at 8.7% of the equity portfolio, followed by $ISRG and $RGEN. During the quarter the fund opened 16 new positions and exited 14 — including a new stake in $ISRG and a full exit from $DXCM. The portfolio is most concentrated in Healthcare (87.7% of disclosed assets). All figures are sourced directly from Iron Triangle Partners LP’s Form 13F-HR filing with the SEC under CIK 1779763.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q4 2025
Click any card to unlockTop Holdings
- 47.1#1,611
Quality
$75.7M379,728 sh - 81.4#30
Quality
$53.5M94,459 sh - 54.1#1,238
Quality
$52.5M320,474 sh - —
Quality
$49.7M292,170 sh - 59.5
Quality
$41.3M980,391 sh - 79.9
Quality
$40.1M420,773 sh - 69.9
Quality
$39.9M105,167 sh - 43.1
Quality
$37.7M3,491,663 sh - 89.3
Quality
$37.7M35,045 sh - 44.9
Quality
$37.4M794,380 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.$CRL | 47.1#1,611 | $75.7M | 379,728 |
 INTUITIVE SURGICAL INC$ISRG | 81.4#30 | $53.5M | 94,459 |
 REPLIGEN CORP$RGEN | 54.1#1,238 | $52.5M | 320,474 |
 Jazz Pharmaceuticals plc$JAZZ | — | $49.7M | 292,170 |
 VERACYTE, INC.$VCYT | 59.5 | $41.3M | 980,391 |
 BOSTON SCIENTIFIC CORP$BSX | 79.9 | $40.1M | 420,773 |
 WATERS CORP /DE/$WAT | 69.9 | $39.9M | 105,167 |
 Brookdale Senior Living Inc.$BKD | 43.1 | $37.7M | 3,491,663 |
 ELI LILLY & Co$LLY | 89.3 | $37.7M | 35,045 |
 BRUKER CORP$BRKR | 44.9 | $37.4M | 794,380 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Iron Triangle Partners LP's 27 positions.
Showing top 10 of 27 holdings.
Sector Allocation
Healthcare
$766.9M
Technology
$107.8M
Full Holdings — Iron Triangle Partners LP (Q4 2025)
All 27 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $75.7M | 8.7% | +42% | 47.1 |
| 2 | $ISRG | INTUITIVE SURGICAL INC | $53.5M | 6.1% | NEW | 81.4 |
| 3 | $RGEN | REPLIGEN CORP | $52.5M | 6.0% | +19% | 54.1 |
| 4 | $JAZZ | Jazz Pharmaceuticals plc | $49.7M | 5.7% | +95% | — |
| 5 | $VCYT | VERACYTE, INC. | $41.3M | 4.7% | +102% | 59.5 |
| 6 | $BSX | BOSTON SCIENTIFIC CORP | $40.1M | 4.6% | NEW | 79.9 |
| 7 | $WAT | WATERS CORP /DE/ | $39.9M | 4.6% | NEW | 69.9 |
| 8 | $BKD | Brookdale Senior Living Inc. | $37.7M | 4.3% | +23% | 43.1 |
| 9 | $LLY | ELI LILLY & Co | $37.7M | 4.3% | -29% | 89.3 |
| 10 | $BRKR | BRUKER CORP | $37.4M | 4.3% | NEW | 44.9 |
| 11 |  $VRTX | VERTEX PHARMACEUTICALS INC / MA | $34.9M | 4.0% | NEW | 76.6 |
| 12 |  $CVS | CVS HEALTH Corp | $34.3M | 3.9% | -46% | 51.3 |
| 13 |  $FTRE | Fortrea Holdings Inc. | $34.3M | 3.9% | NEW | 31.4 |
| 14 |  $MMSI | MERIT MEDICAL SYSTEMS INC | $34.0M | 3.9% | NEW | 60.1 |
| 15 |  $BTSG | BrightSpring Health Services, Inc. | $33.6M | 3.8% | -28% | 64.3 |
| 16 |  $DOCS | Doximity, Inc. | $30.4M | 3.5% | +227% | 77.5 |
| 17 |  $TECH | BIO-TECHNE Corp | $27.5M | 3.1% | NEW | 59.6 |
| 18 |  $ATEC | Alphatec Holdings, Inc. | $27.1M | 3.1% | NEW | 37.7 |
| 19 |  $AHCO | AdaptHealth Corp. | $26.0M | 3.0% | +36% | 47.9 |
| 20 |  $NVST | Envista Holdings Corp | $25.8M | 3.0% | NEW | 49.8 |
| 21 |  $UNH | UNITEDHEALTH GROUP INC | $23.1M | 2.6% | NEW | 66.8 |
| 22 |  $ABT | ABBOTT LABORATORIES | $22.0M | 2.5% | NEW | 67 |
| 23 |  $IDYA | IDEAYA Biosciences, Inc. | $16.2M | 1.9% | +73% | 10.5 |
| 24 |  $BHVN | Biohaven Ltd. | $10.8M | 1.2% | NEW | — |
| 25 |  $XENE | Xenon Pharmaceuticals Inc. | $10.5M | 1.2% | NEW | 12.9 |
| 26 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $9.5M | 1.1% | NEW | 26.8 |
| 27 |  $MLYS | Mineralys Therapeutics, Inc. | $9.3M | 1.1% | NEW | — |
New Positions (16)
$ISRG INTUITIVE SURGICAL INC$53.5M$BSX BOSTON SCIENTIFIC CORP$40.1M$WAT WATERS CORP /DE/$39.9M$BRKR BRUKER CORP$37.4M$VRTX VERTEX PHARMACEUTICALS INC / MA$34.9M$FTRE Fortrea Holdings Inc.$34.3M$MMSI MERIT MEDICAL SYSTEMS INC$34.0M$TECH BIO-TECHNE Corp$27.5M$ATEC Alphatec Holdings, Inc.$27.1M$NVST Envista Holdings Corp$25.8M$UNH UNITEDHEALTH GROUP INC$23.1M$ABT ABBOTT LABORATORIES$22.0M$BHVN Biohaven Ltd.$10.8M$XENE Xenon Pharmaceuticals Inc.$10.5M$DNTH Dianthus Therapeutics, Inc. /DE/$9.5MExited Positions (14)
$DXCM DEXCOM INC
$ABBV AbbVie Inc.
$MDT Medtronic plc
$GKOS GLAUKOS Corp
$THC TENET HEALTHCARE CORP
$EXK ENDEAVOUR SILVER CORP
$MDGL MADRIGAL PHARMACEUTICALS, INC.
$GH Guardant Health, Inc.
$CAH CARDINAL HEALTH INC
$NBIX NEUROCRINE BIOSCIENCES INC
$WST WEST PHARMACEUTICAL SERVICES INC
$FOLD AMICUS THERAPEUTICS, INC.
$ARGX ARGENX SEBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Iron Triangle Partners LP including:
Track Iron Triangle Partners LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Iron Triangle Partners LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Iron Triangle Partners LP
13F Pro is an AI hedge fund tracker and stock research platform. For Iron Triangle Partners LP (SEC CIK: 1779763), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Iron Triangle Partners LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.